This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News For Oct 31, 2019
by Zacks Equity Research
Benchmarks closed in the green on Wednesday as the Federal Reserve cut rates for the third time this year, and Chairman Jerome Powell signaled no rate hikes until he witness a "really significant" rise in inflation.
Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More
by Urmimala Biswas
Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.
Bayer (BAYRY) Q3 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer's (BAYRY) earnings beat and revenues rise on the back of growth across all reported segments in the third quarter. The company updates guidance to include impact of discontinued operations.
Merck (MRK) Beats on Q3 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in third-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.
Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q3 Earnings?
by Zacks Equity Research
Rising competition in international markets for Humira might have hurt AbbVie's (ABBV) top line in the third quarter. However, strong growth of Imbruvica is expected to have offset the loss.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.
Lannett (LCI) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet's (LCI) fiscal first-quarter 2020 results are likely to reflect strong performance of its anti-psychosis and cardiovascular drugs.
Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA
by Kinjel Shah
Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) release Q3 results. FDA approves Glaxo's (GSK) Zejula and AstraZeneca's Farxiga for more patients. CHMP gives nod to several drugs
Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3
by Zacks Equity Research
Alkermes (ALKS) beats estimates in the third quarter of 2019. Its proprietary products, especially Aristada, drive revenues.
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Medical Products' Earnings Roster for Oct 23: TMO, BSX & More
by Zacks Equity Research
Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.
Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.
J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos
by Zacks Equity Research
J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.
Stock Market News for Oct 21, 2019
by Zacks Equity Research
U.S. stocks closed sharply lower on Friday owing to negative report of two important Dow stocks, disappointing growth of China in the third quarter and Brexit-related uncertainties.
Stocks Mostly Post Modest Gains During the First Week of Earnings Season
by David Borun
More than 80% of reporting companies beat estimates, but isolated bad news keeps a cap on the Dow
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Pfizer, Qualcomm and Mitsubishi UFJ Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Boeing, Pfizer, Qualcomm and Mitsubishi UFJ Financial
3 Medical Product Stocks Likely to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow
by Kinjel Shah
FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3
Top Stock Reports for Johnson & Johnson, Boeing & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Boeing (BA) and Pfizer (PFE).
JNJ Beats, Ups View: Healthcare ETFs to Buy
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
Stock Market News for Oct 16, 2019
by Zacks Equity Research
Wall Street closed Tuesday's trading session at more than three-week high, thanks to better-than expected third quarter 2019 earnings of mostly major American banks.
Johnson & Johnson (JNJ) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.00% and 3.22%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
by Zacks Equity Research
FDA approves Johnson & Johnson's (JNJ) Xarelto to prevent blood clots in hospitalized acutely ill medical patients.
J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View
by Zacks Equity Research
J&J (JNJ) comes up with encouraging third-quarter 2019 results.
Initial Q3 Results Are Better-Than-Expected
by Zacks Equity Research
Initial Q3 Results Are Better-Than-Expected